Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Longbio of Suzhou Says LP-003 Effective in Patients with Allergic Rhinitis

publication date: Feb 26, 2024

Longbio Pharma (Suzhou) released results from a Phase II trial of its lead drug, LP-003, showing 100mg of LP-003 offered the same efficacy as 300mg of omalizumab, the current standard of care, in patients with allergic rhinitis. Both therapies are anti-IgE antibodies, but LP-003, which binds a new target, has shown better bioactivity than omalizumab in subgroup analysis. LP-003 is a novel monoclonal anti-IgE antibody that was generated and engineered by Dr. Nai-chau Sun, who co-founded Longbio and also invented omalizumab. Longbio believes LP-003 has potential to be best-in-class. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital